Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

<p>Information of ATCC cell lines</p>

Сохранить в:

Библиографические подробности
Главный автор:	Seung Yeon Oh (15051017) (author)
Другие авторы:	You Won Lee (15051020) (author), Eun Ji Lee (15051023) (author), Jae Hwan Kim (15051026) (author), YoungJoon Park (15051029) (author), Seong Gu Heo (15032490) (author), Mi Ra Yu (15051032) (author), Min Hee Hong (15014541) (author), John DaSilva (15051035) (author), Christopher Daly (15030374) (author), Byoung Chul Cho (15032496) (author), Sun Min Lim (15051038) (author), Mi Ran Yun (15032484) (author)
Опубликовано:	2025
Предметы:	Cancer Therapeutic Research and Development Drug Resistance Clinical drug resistance Lung Cancer Translational Research
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
по: Seung Yeon Oh (15051017)
Опубликовано: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
по: Seung Yeon Oh (15051017)
Опубликовано: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
по: Seung Yeon Oh (15051017)
Опубликовано: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
по: Seung Yeon Oh (15051017)
Опубликовано: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
по: Seung Yeon Oh (15051017)
Опубликовано: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
по: Seung Yeon Oh (15051017)
Опубликовано: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
по: Seung Yeon Oh (15051017)
Опубликовано: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
по: Seung Yeon Oh (15051017)
Опубликовано: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
по: Seung Yeon Oh (15051017)
Опубликовано: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
по: Seung Yeon Oh (15051017)
Опубликовано: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
по: Seung Yeon Oh (15051017)
Опубликовано: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
по: Chong Kin Liam (15331321)
Опубликовано: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
по: Chong Kin Liam (15331321)
Опубликовано: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
по: Chong Kin Liam (15331321)
Опубликовано: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
по: Chong Kin Liam (15331321)
Опубликовано: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
по: Yufang Bao (15386826)
Опубликовано: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
по: Yufang Bao (15386826)
Опубликовано: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
по: Yufang Bao (15386826)
Опубликовано: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
по: Yufang Bao (15386826)
Опубликовано: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
по: Yufang Bao (15386826)
Опубликовано: (2025)

Table S5 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
по: Nina Müller (16721126)
Опубликовано: (2025)

Table S6 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
по: Nina Müller (16721126)
Опубликовано: (2025)

Table S7 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
по: Nina Müller (16721126)
Опубликовано: (2025)

Table S8 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
по: Nina Müller (16721126)
Опубликовано: (2025)

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
по: Nicole A. Traphagen (16677391)
Опубликовано: (2025)

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
по: Nicole A. Traphagen (16677391)
Опубликовано: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
по: Alex C.H. Liu (14961921)
Опубликовано: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
по: Alex C.H. Liu (14961921)
Опубликовано: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
по: Alex C.H. Liu (14961921)
Опубликовано: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
по: Alex C.H. Liu (14961921)
Опубликовано: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
по: Alex C.H. Liu (14961921)
Опубликовано: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
по: Alex C.H. Liu (14961921)
Опубликовано: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
по: Dahihm Kim (16546203)
Опубликовано: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
по: Dahihm Kim (16546203)
Опубликовано: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
по: Dahihm Kim (16546203)
Опубликовано: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
по: Dahihm Kim (16546203)
Опубликовано: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
по: Dahihm Kim (16546203)
Опубликовано: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
по: Dahihm Kim (16546203)
Опубликовано: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
по: Dahihm Kim (16546203)
Опубликовано: (2025)

Supplementary Table S1 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
по: Phyllis S.Y. Chong (17141520)
Опубликовано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_drvnpg474m9rg23do963akdjv8